Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease
Dennis J. Selkoe
Dennis J. Selkoe
Published November 15, 2002
Citation Information: J Clin Invest. 2002;110(10):1375-1381. https://doi.org/10.1172/JCI16783.
View: Text | PDF
Perspective Article has an altmetric score of 9

Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease

  • Text
  • PDF
Abstract

Perspective

Authors

Dennis J. Selkoe

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Schematic diagrams of the APP and its principal metabolic derivatives. T...
Schematic diagrams of the APP and its principal metabolic derivatives. The first line depicts the largest of the known APP alternate splice forms, comprising 770 amino acids. Regions of interest are indicated at their correct relative positions. A 17-residue signal peptide occurs at the N-terminus (box with vertical lines). Two alternatively spliced exons of 56 and 19 amino acids are inserted at residue 289; the first contains a serine protease inhibitor domain of the Kunitz type (KPI). A single membrane-spanning domain (TM) at amino acids 700–723 is indicated by the vertical dotted lines. The Aβ fragment includes 28 residues just outside the membrane plus the first 12–14 residues of the TM domain. In the second line, the sequence within APP that contains the Aβ and TM regions is expanded. The underlined residues represent the Aβ1-42 peptide. The blue letters below the wild-type sequence indicate the currently known missense mutations identified in certain patients with AD and/or hereditary cerebral hemorrhage with amyloidosis. The three-digit numbers are codon numbers (βAPP770 isoform). In the third line, the arrow indicates the site (after residue 687) of a cleavage by α-secretase that enables secretion of the large, soluble ectodomain of APP (APPs - α) into the medium and retention of the 83-residue C-terminal fragment (C83) in the membrane. C83 can undergo cleavage by the protease called γ-secretase at residue 711 or residue 713 to release the p3 peptides. The fourth line depicts the alternative proteolytic cleavage after residue 671 by β-secretase that results in the secretion of the slightly truncated APPs β molecule and the retention of a 99-residue C-terminal fragment. C99 can also undergo cleavage by γ-secretase to release the Aβ peptides. Cleavage of both C83 and C99 by γ-secretase releases the AICD into the cytoplasm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 11 patents
57 readers on Mendeley
See more details